{"filing":{"accession_number":"0001193125-26-337974","cik":"0001563880","ticker":"TRVI","company_name":"Trevi Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"trvi-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-20260806.htm"},"events":[{"id":25608,"run_id":23242,"accession_number":"0001193125-26-337974","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($15.2M vs $9.4M YoY), G\u0026A expenses ($5.4M vs $4.3M YoY), net loss ($17.8M vs $12.3M YoY), and cash position ($318.9M). The filing also includes selected balance sheet and statement of operations data, which are typical components of an earnings announcement.","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26488,"accession_number":"0001193125-26-337974","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($15.2M vs $9.4M YoY), G\u0026A expenses ($5.4M vs $4.3M YoY), net loss ($17.8M vs $12.3M YoY), and cash position ($318.9M). The filing also includes selected balance sheet and statement of operations data, which are typical components of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:43.797963+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26488,"accession_number":"0001193125-26-337974","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($15.2M vs $9.4M YoY), G\u0026A expenses ($5.4M vs $4.3M YoY), net loss ($17.8M vs $12.3M YoY), and cash position ($318.9M). The filing also includes selected balance sheet and statement of operations data, which are typical components of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:43.797963+00:00","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-08-06"}]}